168 related articles for article (PubMed ID: 38512662)
1. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
Horsley D; Rickard JE; Vorley T; Leeper MF; Wischik CM; Harrington CR
Methods Mol Biol; 2024; 2754():93-104. PubMed ID: 38512662
[TBL] [Abstract][Full Text] [Related]
2. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
Rickard JE; Horsley D; Wischik CM; Harrington CR
Methods Mol Biol; 2017; 1523():129-140. PubMed ID: 27975248
[TBL] [Abstract][Full Text] [Related]
3. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
4. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
5. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
6. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
7. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
8. Tau protein aggregation: Key features to improve drug discovery screening.
Giovannini J; Smeralda W; Jouanne M; Sopkova-de Oliveira Santos J; Catto M; Voisin-Chiret AS
Drug Discov Today; 2022 May; 27(5):1284-1297. PubMed ID: 35085785
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies.
Altendorf T; Gering I; Santiago-Schübel B; Aghabashlou Saisan S; Tamgüney G; Tusche M; Honold D; Schemmert S; Hoyer W; Mohrlüder J; Willbold D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768484
[TBL] [Abstract][Full Text] [Related]
10. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
11. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
13. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
[TBL] [Abstract][Full Text] [Related]
14. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
15. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
[TBL] [Abstract][Full Text] [Related]
17. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity.
Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
Neurodegener Dis; 2017; 17(2-3):73-82. PubMed ID: 27760426
[TBL] [Abstract][Full Text] [Related]
18. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.
Wang C; Terrigno M; Li J; Distler T; Pandya NJ; Ebeling M; Tyanova S; Hoozemans JJM; Dijkstra AA; Fuchs L; Xiang S; Bonni A; Grüninger F; Jagasia R
Neuron; 2023 Sep; 111(17):2660-2674.e9. PubMed ID: 37385246
[TBL] [Abstract][Full Text] [Related]
19. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
20. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
